JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

A

145.98

+0.05%↑

JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

A

145.98

+0.05%↑

JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

A

145.98

+0.05%↑

JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

A

145.98

+0.05%↑

JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

A

145.98

+0.05%↑

Search

Actinium Pharmaceuticals Inc

Cerrado

1.44 -4.64

Resumen

Variación precio

24h

Actual

Mínimo

1.4

Máximo

1.49

Métricas clave

By Trading Economics

Ingresos

9.1M

-6.9M

Margen de beneficio

-821.235

Empleados

27

EBITDA

9.1M

-7.5M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+198.01% upside

Dividendos

By Dow Jones

Próximas Ganancias

12 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-4.4M

47M

Apertura anterior

6.08

Cierre anterior

1.44

Actinium Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

22 oct 2025, 22:47 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22 oct 2025, 22:13 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22 oct 2025, 21:20 UTC

Ganancias

Correction to IBM 3Q Sales Jump Article

22 oct 2025, 20:57 UTC

Ganancias

SAP Posts Higher 3Q Revenue, Operating Profit

22 oct 2025, 23:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 oct 2025, 23:46 UTC

Charlas de Mercado

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22 oct 2025, 23:41 UTC

Charlas de Mercado

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 oct 2025, 23:38 UTC

Charlas de Mercado

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 oct 2025, 23:15 UTC

Ganancias

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22 oct 2025, 22:28 UTC

Charlas de Mercado

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22 oct 2025, 22:02 UTC

Ganancias

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22 oct 2025, 21:59 UTC

Adquisiciones, fusiones, absorciones

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22 oct 2025, 21:58 UTC

Adquisiciones, fusiones, absorciones

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22 oct 2025, 21:57 UTC

Adquisiciones, fusiones, absorciones

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22 oct 2025, 21:56 UTC

Adquisiciones, fusiones, absorciones

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22 oct 2025, 21:47 UTC

Adquisiciones, fusiones, absorciones

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22 oct 2025, 21:47 UTC

Ganancias

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 oct 2025, 21:47 UTC

Adquisiciones, fusiones, absorciones

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22 oct 2025, 21:46 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22 oct 2025, 21:45 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22 oct 2025, 21:45 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22 oct 2025, 21:28 UTC

Charlas de Mercado
Ganancias

Correction to Alcoa Tariff Market Talk

22 oct 2025, 21:25 UTC

Ganancias

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22 oct 2025, 21:17 UTC

Ganancias

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22 oct 2025, 21:09 UTC

Charlas de Mercado
Ganancias

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22 oct 2025, 21:00 UTC

Charlas de Mercado

ESG Roundup: Market Talk

22 oct 2025, 20:59 UTC

Ganancias

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 oct 2025, 20:51 UTC

Ganancias

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

22 oct 2025, 20:44 UTC

Ganancias

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Comparación entre iguales

Cambio de precio

Actinium Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

198.01% repunte

Estimación a 12 meses

Media 4.5 USD  198.01%

Máximo 5 USD

Mínimo 4 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Actinium Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

2

Comprar

0

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.
help-icon Live chat